Navigation Links
SyntheMed Announces FDA Clearance of SinusShield(TM)
Date:11/19/2008

ISELIN, N.J., Nov. 19 /PRNewswire-FirstCall/ -- SyntheMed, Inc. (OTC Bulletin Board: SYMD) announced today that it has received FDA 510(k) clearance to market SinusShield(TM), a bioresorbable membrane intended to prevent post-operative adhesions in nasal and sinus surgical procedures. There are approximately two million nasal and sinus procedures performed annually in the United States.

Robert P. Hickey, SyntheMed's President & CEO stated, "SinusShield represents an example of our strategy to capitalize on our proprietary polymer film technology in new surgical applications both in the United States and international markets." The company is in discussion with prospective partners with the distribution infrastructure to service the office-based and hospital outpatient sites where these procedures are performed.

About SinusShield(TM)

SinusShield is a bioresorbable polymer membrane indicated for use in patients undergoing nasal and sinus surgical procedures as a space-occupying stent to separate and prevent adhesions between mucosal surfaces. During surgical procedures involving the sinuses and sinus passages, it is common for surgeons to place silastic tubes or sheets in the sinus passages to prevent blockage caused by adhesion formation; however, these materials must often be removed in a second procedure. SinusShield is intended to prevent blockage and then biodegrade thereby eliminating the second procedure.

About SyntheMed, Inc.

SyntheMed, Inc. is a biomaterials company engaged in the development and commercialization of anti-adhesion products and other surgical implants based on its proprietary bioresorbable polymer technology. The company is developing a portfolio of anti-adhesion products led by REPEL-CV(R) Adhesion Barrier, an anti-adhesion product intended for use in open heart surgical procedures. REPEL-CV is currently marketed internationally and is awaiting FDA approval to market in the United States.

Statements in this press release that are not statements of historical fact constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve market potential, distribution strategies, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such risks and uncertainties include but are not limited to (i) potential adverse developments regarding the company's efforts to obtain and maintain required regulatory approvals; (ii) potential inability to secure funding as and when needed to support the company's future activities and (iii) unanticipated delays associated with manufacturing and marketing activities. Reference is made to the Company's Annual Report on Form 10-KSB for the year ended December 31, 2007 for a description of these, as well as other, risks and uncertainties.


'/>"/>
SOURCE SyntheMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. SyntheMed to Host Symposium on Adhesions in Cardiac Surgery
2. SyntheMed to Present at the Acumen BioFin Conference
3. SyntheMed Files Universal Shelf Registration
4. SyntheMed to Present at Canaccord Adams Small-Cap Orthopedics Conference
5. SyntheMed To Present at the AdvaMed 2008 MedTech Conference
6. SyntheMed Completes $4.0 Million Equity Placement
7. SyntheMed Announces New Management Appointments
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... States (PRWEB) , ... September 22, 2017 , ... ... for venous leg ulcers is now being assessed in clinical trials in the ... trial please talk to your nurse or physician or find your nearest participating ...
(Date:9/21/2017)... ... September 21, 2017 , ... Dr. Greg Leyer, Chief ... NV on September 27th. His presentation is at 12:10pm in the Probiotics Resource Center, ... present at SupplySide West and discuss how probiotics have shown impressive data in areas ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... Each relaunch of the portal includes new features that facilitate streamlined and compliant ... seek to remain at the forefront of medical advancements, they rely on efficiencies ...
(Date:9/21/2017)... ... September 21, 2017 , ... Today, BioPharma Institute, a ... the addition of 5 new courses to its prospectus. These include the eagerly-awaited ... CFR Part 11 on Electronic Records and Electronic Signatures (Part 11 of Title ...
Breaking Biology Technology:
(Date:5/23/2017)... , May 23, 2017  Hunova, the first robotic gym for the ... been officially launched in Genoa, Italy . The first ... and the USA . The technology was developed ... market by the IIT spin-off Movendo Technology thanks to a 10 million ... News Release, please click: ...
(Date:4/24/2017)... April 24, 2017 Janice Kephart ... with  Identity Strategy Partners, LLP (IdSP) , today ... without President Trump,s March 6, 2017 Executive ... , refugee vetting can be instilled with greater confidence, ... now, all refugee applications are suspended by until ...
(Date:4/13/2017)... UBM,s Advanced Design and Manufacturing event in ... and evolving technology through its 3D Printing and Smart ... the expo portion of the event and feature a ... on trending topics within 3D printing and smart manufacturing. ... will take place June 13-15, 2017 at the Jacob K. ...
Breaking Biology News(10 mins):